RAPS Workshop: Regulatory Requirements for Investigational Combination Products in Cell and Gene Therapy - A Global CMC Perspective (US, EU, Canada)

Explore the evolving regulatory landscape for CGT combination products focusing on device development and potency assay requirements.

Cell and gene therapy (CGT) development is entering a pivotal phase, driven by increasing reliance on integrated delivery systems, medical devices, and ancillary components. These therapies are no longer defined solely by the biologic or cellular product, but by the performance, control, and regulatory compliance of the complete combination product.

As regulatory expectations evolve across global health authorities, sponsors face growing complexity in aligning Chemistry, Manufacturing, and Controls (CMC) strategies for investigational CGT combination products. Differences in regulatory frameworks, device expectations, human factors requirements, and potency assessment approaches can introduce significant development risk if not addressed early.

This advanced, two-hour workshop provides a focused and practical exploration of global CMC regulatory considerations for investigational CGT combination products, with emphasis on FDA, EMA, and Health Canada expectations. The program is designed to equip regulatory, CMC, and technical professionals with actionable strategies to support early- and mid-stage development while minimizing downstream regulatory risk.

Key Areas of Focus

  • Global regulatory expectations for investigational CGT combination products
  • CMC Module 3 considerations and cross-regional alignment strategies
  • Device development: Review of regulatory guidance for device development, including design controls and risk management
  • Human factors and usability considerations for CGT delivery systems
  • Potency strategies for cell and gene therapy products, including assay design, qualification, and validation

Learning Objectives

Upon completion of this workshop, participants will be able to:

  • Interpret key CMC Module 3 expectations for CGT combination products across FDA, EMA, and Health Canada.
  • Apply essential regulatory principles for medical devices, including design controls, risk management, and human factors, within CGT development programs.
  • Design and justify potency strategies that meet global regulatory expectations for cell and gene therapy products.

Who Should Attend?

  • Regulatory Affairs professionals supporting cell and gene therapy or combination product programs.
  • CMC and Technical Development professionals contributing to global regulatory submissions.
  • Device development and engineering professionals working on CGT delivery systems.
  • Scientists responsible for potency assay development and regulatory justification.
  • Quality and compliance professionals overseeing combination product requirements.

Audience Learning Level

Intermediate: Content is designed based upon the assumption that individuals have basic knowledge of the topic(s) and/or demonstrated competence related to the topic(s). Higher-level concepts are introduced during lectures; exercises requiring synthesis and/or application of concepts are incorporated into the activity.

Agenda

Time ET

Topic

9:00 – 9:10 am

Welcome and Workshop Introduction

9:10 – 9:30 am

Global CMC Module 3 Expectations for CGT Combination Products

9:30 – 10:05 am

Medical Device Regulatory Principles and Human Factors Considerations

10:05 – 10:35 am

Potency Strategies for Cell and Gene Therapy Products

10:35 – 11:00 am

Case Study: Building a Global CMC Strategy for an Investigational Combination Product 

Cancellations and Refunds

RAPS reserves the right to cancel this program at its sole discretion. RAPS will not be responsible for travel or other costs incurred due to cancellation. All cancellation requests must be submitted in writing to [email protected]Cancellations will receive a full refund minus a 20% administrative fee. RAPS is unable to accept cancellations by phone.

Substitutions

Paid registration substitutions may be accepted with written approval from RAPS for requests received before the start of the event. To transfer a registration, email [email protected] with the event title, name of the original registrant and the contact information for the new attendee.

Proof of Attendance

A certificate of attendance can be downloaded from the RAPS Learning Portal following the event.

Questions

Contact the RAPS Support Center:
Call +1 301 770 2920, ext. 200 (8:30 am–5:30 pm EST, Monday–Friday) or email [email protected].

Speakers

Sai Bhamidipati MS, RAC

Sai Bhamidipati MS, RAC

Director of Regulatory CMC, Moderna

Find out more

Kai-Roy Wang MS

Kai-Roy Wang MS

Associate Director Device Development & Manufacturing, Viridian Therapeutics

Find out more

×

Welcome to the new RAPS Digital Experience

We have completed our migration to a new platform and are pleased to introduce the updated site.

What to expect: If you have an existing login, please RESET YOUR PASSWORD before signing in. After you log in for the first time, you will be prompted to confirm your profile preferences, which will be used to personalize content.

We encourage you to explore the new website and visit your updated My RAPS page. If you need assistance, please review our FAQ page.

We welcome your feedback. Please let us know how we can continue to improve your experience.